Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 10Thoracic 7Genitourinary 7Head & Neck 6Breast 6Other 4Tumor-Agnostic 3Sarcoma 2Other neoplasm 2Other hematologic neoplasm 2Lymphoid 2Classical hematology 2CNS 2Plasma cell 1Other solid neoplasm 1Myeloid 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Neoplasms 2Burns 2Anemia, Sickle Cell 2Pain 1Breakthrough Pain 1Agnosia 1

Interventions

Cyclophosphamide 93fludarabine phosphate 86Busulfan 63Cyclosporine 57Peripheral Blood Stem Cell Transplantation 54Mycophenolic Acid 54Whole-Body Irradiation 53Epoetin Alfa 53Antilymphocyte Serum 43fludarabine 42Filgrastim 41Cytarabine 41Tacrolimus 39Melphalan 38Darbepoetin alfa 38Methotrexate 34Radiotherapy 32Cord Blood Stem Cell Transplantation 28Granulocyte Colony-Stimulating Factor 23Methylprednisolone 21Etoposide 21apixaban 18eltrombopag 16Thiotepa 16Dalteparin 16ferric carboxymaltose 14Daunorubicin 14Azacitidine 14Alemtuzumab 14thymoglobulin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Fentanyl × Classical hematology × Clear all
NCT00236041 2014-05-09

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
38 enrolled
Classical hematology

Agnosia, Anemia, Sickle Cell, Burns, Neoplasms, Breakthrough Pain

NCT00236093 2014-05-09

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
Classical hematology

Anemia, Sickle Cell, Burns, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡